Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
6,786
archived clinical trials in
Dermatology

A Study of the Efficacy and Safety of Omalizumab Through 48 Weeks in Participants With Chronic Idiopathic Urticaria
XTEND-CIU (Xolair Treatment Efficacy of Longer Duration in Chronic Idiopathic Urticaria): A Phase IV, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Omalizumab Through 48 Weeks in Patients With Chronic Idiopathic Urticaria
Status: Enrolling
Updated:  3/26/2018
Winthrop University Hospital
mi
from
Mineola, NY
A Study of the Efficacy and Safety of Omalizumab Through 48 Weeks in Participants With Chronic Idiopathic Urticaria
XTEND-CIU (Xolair Treatment Efficacy of Longer Duration in Chronic Idiopathic Urticaria): A Phase IV, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Omalizumab Through 48 Weeks in Patients With Chronic Idiopathic Urticaria
Status: Enrolling
Updated: 3/26/2018
Winthrop University Hospital
mi
from
Mineola, NY
Click here to add this to my saved trials
A Study of the Efficacy and Safety of Omalizumab Through 48 Weeks in Participants With Chronic Idiopathic Urticaria
XTEND-CIU (Xolair Treatment Efficacy of Longer Duration in Chronic Idiopathic Urticaria): A Phase IV, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Omalizumab Through 48 Weeks in Patients With Chronic Idiopathic Urticaria
Status: Enrolling
Updated:  3/26/2018
AAIR Research Center
mi
from
Rochester, NY
A Study of the Efficacy and Safety of Omalizumab Through 48 Weeks in Participants With Chronic Idiopathic Urticaria
XTEND-CIU (Xolair Treatment Efficacy of Longer Duration in Chronic Idiopathic Urticaria): A Phase IV, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Omalizumab Through 48 Weeks in Patients With Chronic Idiopathic Urticaria
Status: Enrolling
Updated: 3/26/2018
AAIR Research Center
mi
from
Rochester, NY
Click here to add this to my saved trials
A Study of the Efficacy and Safety of Omalizumab Through 48 Weeks in Participants With Chronic Idiopathic Urticaria
XTEND-CIU (Xolair Treatment Efficacy of Longer Duration in Chronic Idiopathic Urticaria): A Phase IV, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Omalizumab Through 48 Weeks in Patients With Chronic Idiopathic Urticaria
Status: Enrolling
Updated:  3/26/2018
University of Rochester Medical Center; University Dermatology Associates
mi
from
Rochester, NY
A Study of the Efficacy and Safety of Omalizumab Through 48 Weeks in Participants With Chronic Idiopathic Urticaria
XTEND-CIU (Xolair Treatment Efficacy of Longer Duration in Chronic Idiopathic Urticaria): A Phase IV, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Omalizumab Through 48 Weeks in Patients With Chronic Idiopathic Urticaria
Status: Enrolling
Updated: 3/26/2018
University of Rochester Medical Center; University Dermatology Associates
mi
from
Rochester, NY
Click here to add this to my saved trials
A Study of the Efficacy and Safety of Omalizumab Through 48 Weeks in Participants With Chronic Idiopathic Urticaria
XTEND-CIU (Xolair Treatment Efficacy of Longer Duration in Chronic Idiopathic Urticaria): A Phase IV, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Omalizumab Through 48 Weeks in Patients With Chronic Idiopathic Urticaria
Status: Enrolling
Updated:  3/26/2018
Allergy Partners of Western NC
mi
from
Asheville, NC
A Study of the Efficacy and Safety of Omalizumab Through 48 Weeks in Participants With Chronic Idiopathic Urticaria
XTEND-CIU (Xolair Treatment Efficacy of Longer Duration in Chronic Idiopathic Urticaria): A Phase IV, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Omalizumab Through 48 Weeks in Patients With Chronic Idiopathic Urticaria
Status: Enrolling
Updated: 3/26/2018
Allergy Partners of Western NC
mi
from
Asheville, NC
Click here to add this to my saved trials
A Study of the Efficacy and Safety of Omalizumab Through 48 Weeks in Participants With Chronic Idiopathic Urticaria
XTEND-CIU (Xolair Treatment Efficacy of Longer Duration in Chronic Idiopathic Urticaria): A Phase IV, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Omalizumab Through 48 Weeks in Patients With Chronic Idiopathic Urticaria
Status: Enrolling
Updated:  3/26/2018
Allergy and Respiratory Center
mi
from
Canton, OH
A Study of the Efficacy and Safety of Omalizumab Through 48 Weeks in Participants With Chronic Idiopathic Urticaria
XTEND-CIU (Xolair Treatment Efficacy of Longer Duration in Chronic Idiopathic Urticaria): A Phase IV, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Omalizumab Through 48 Weeks in Patients With Chronic Idiopathic Urticaria
Status: Enrolling
Updated: 3/26/2018
Allergy and Respiratory Center
mi
from
Canton, OH
Click here to add this to my saved trials
A Study of the Efficacy and Safety of Omalizumab Through 48 Weeks in Participants With Chronic Idiopathic Urticaria
XTEND-CIU (Xolair Treatment Efficacy of Longer Duration in Chronic Idiopathic Urticaria): A Phase IV, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Omalizumab Through 48 Weeks in Patients With Chronic Idiopathic Urticaria
Status: Enrolling
Updated:  3/26/2018
Bernstein Clinical Research Center
mi
from
Cincinnati, OH
A Study of the Efficacy and Safety of Omalizumab Through 48 Weeks in Participants With Chronic Idiopathic Urticaria
XTEND-CIU (Xolair Treatment Efficacy of Longer Duration in Chronic Idiopathic Urticaria): A Phase IV, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Omalizumab Through 48 Weeks in Patients With Chronic Idiopathic Urticaria
Status: Enrolling
Updated: 3/26/2018
Bernstein Clinical Research Center
mi
from
Cincinnati, OH
Click here to add this to my saved trials
A Study of the Efficacy and Safety of Omalizumab Through 48 Weeks in Participants With Chronic Idiopathic Urticaria
XTEND-CIU (Xolair Treatment Efficacy of Longer Duration in Chronic Idiopathic Urticaria): A Phase IV, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Omalizumab Through 48 Weeks in Patients With Chronic Idiopathic Urticaria
Status: Enrolling
Updated:  3/26/2018
Toledo Inst of Clin Research
mi
from
Toledo, OH
A Study of the Efficacy and Safety of Omalizumab Through 48 Weeks in Participants With Chronic Idiopathic Urticaria
XTEND-CIU (Xolair Treatment Efficacy of Longer Duration in Chronic Idiopathic Urticaria): A Phase IV, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Omalizumab Through 48 Weeks in Patients With Chronic Idiopathic Urticaria
Status: Enrolling
Updated: 3/26/2018
Toledo Inst of Clin Research
mi
from
Toledo, OH
Click here to add this to my saved trials
A Study of the Efficacy and Safety of Omalizumab Through 48 Weeks in Participants With Chronic Idiopathic Urticaria
XTEND-CIU (Xolair Treatment Efficacy of Longer Duration in Chronic Idiopathic Urticaria): A Phase IV, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Omalizumab Through 48 Weeks in Patients With Chronic Idiopathic Urticaria
Status: Enrolling
Updated:  3/26/2018
Vital Prospects Clin Res Pc
mi
from
Tulsa, OK
A Study of the Efficacy and Safety of Omalizumab Through 48 Weeks in Participants With Chronic Idiopathic Urticaria
XTEND-CIU (Xolair Treatment Efficacy of Longer Duration in Chronic Idiopathic Urticaria): A Phase IV, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Omalizumab Through 48 Weeks in Patients With Chronic Idiopathic Urticaria
Status: Enrolling
Updated: 3/26/2018
Vital Prospects Clin Res Pc
mi
from
Tulsa, OK
Click here to add this to my saved trials
A Study of the Efficacy and Safety of Omalizumab Through 48 Weeks in Participants With Chronic Idiopathic Urticaria
XTEND-CIU (Xolair Treatment Efficacy of Longer Duration in Chronic Idiopathic Urticaria): A Phase IV, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Omalizumab Through 48 Weeks in Patients With Chronic Idiopathic Urticaria
Status: Enrolling
Updated:  3/26/2018
Asthma, Nasal Disease, and Allergy Research Center of New England
mi
from
East Providence, RI
A Study of the Efficacy and Safety of Omalizumab Through 48 Weeks in Participants With Chronic Idiopathic Urticaria
XTEND-CIU (Xolair Treatment Efficacy of Longer Duration in Chronic Idiopathic Urticaria): A Phase IV, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Omalizumab Through 48 Weeks in Patients With Chronic Idiopathic Urticaria
Status: Enrolling
Updated: 3/26/2018
Asthma, Nasal Disease, and Allergy Research Center of New England
mi
from
East Providence, RI
Click here to add this to my saved trials
A Study of the Efficacy and Safety of Omalizumab Through 48 Weeks in Participants With Chronic Idiopathic Urticaria
XTEND-CIU (Xolair Treatment Efficacy of Longer Duration in Chronic Idiopathic Urticaria): A Phase IV, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Omalizumab Through 48 Weeks in Patients With Chronic Idiopathic Urticaria
Status: Enrolling
Updated:  3/26/2018
National Allergy and Asthma Research, LLC
mi
from
Charleston, SC
A Study of the Efficacy and Safety of Omalizumab Through 48 Weeks in Participants With Chronic Idiopathic Urticaria
XTEND-CIU (Xolair Treatment Efficacy of Longer Duration in Chronic Idiopathic Urticaria): A Phase IV, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Omalizumab Through 48 Weeks in Patients With Chronic Idiopathic Urticaria
Status: Enrolling
Updated: 3/26/2018
National Allergy and Asthma Research, LLC
mi
from
Charleston, SC
Click here to add this to my saved trials
A Study of the Efficacy and Safety of Omalizumab Through 48 Weeks in Participants With Chronic Idiopathic Urticaria
XTEND-CIU (Xolair Treatment Efficacy of Longer Duration in Chronic Idiopathic Urticaria): A Phase IV, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Omalizumab Through 48 Weeks in Patients With Chronic Idiopathic Urticaria
Status: Enrolling
Updated:  3/26/2018
Live Oak Allergy and Asthma Clinic
mi
from
Live Oak, TX
A Study of the Efficacy and Safety of Omalizumab Through 48 Weeks in Participants With Chronic Idiopathic Urticaria
XTEND-CIU (Xolair Treatment Efficacy of Longer Duration in Chronic Idiopathic Urticaria): A Phase IV, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Omalizumab Through 48 Weeks in Patients With Chronic Idiopathic Urticaria
Status: Enrolling
Updated: 3/26/2018
Live Oak Allergy and Asthma Clinic
mi
from
Live Oak, TX
Click here to add this to my saved trials
A Study of the Efficacy and Safety of Omalizumab Through 48 Weeks in Participants With Chronic Idiopathic Urticaria
XTEND-CIU (Xolair Treatment Efficacy of Longer Duration in Chronic Idiopathic Urticaria): A Phase IV, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Omalizumab Through 48 Weeks in Patients With Chronic Idiopathic Urticaria
Status: Enrolling
Updated:  3/26/2018
Allergy and Asthma Research Center
mi
from
San Antonio, TX
A Study of the Efficacy and Safety of Omalizumab Through 48 Weeks in Participants With Chronic Idiopathic Urticaria
XTEND-CIU (Xolair Treatment Efficacy of Longer Duration in Chronic Idiopathic Urticaria): A Phase IV, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Omalizumab Through 48 Weeks in Patients With Chronic Idiopathic Urticaria
Status: Enrolling
Updated: 3/26/2018
Allergy and Asthma Research Center
mi
from
San Antonio, TX
Click here to add this to my saved trials
A Study of the Efficacy and Safety of Omalizumab Through 48 Weeks in Participants With Chronic Idiopathic Urticaria
XTEND-CIU (Xolair Treatment Efficacy of Longer Duration in Chronic Idiopathic Urticaria): A Phase IV, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Omalizumab Through 48 Weeks in Patients With Chronic Idiopathic Urticaria
Status: Enrolling
Updated:  3/26/2018
Timber Lane Allergy-Asth Res
mi
from
South Burlington, VT
A Study of the Efficacy and Safety of Omalizumab Through 48 Weeks in Participants With Chronic Idiopathic Urticaria
XTEND-CIU (Xolair Treatment Efficacy of Longer Duration in Chronic Idiopathic Urticaria): A Phase IV, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Omalizumab Through 48 Weeks in Patients With Chronic Idiopathic Urticaria
Status: Enrolling
Updated: 3/26/2018
Timber Lane Allergy-Asth Res
mi
from
South Burlington, VT
Click here to add this to my saved trials
A Study of the Efficacy and Safety of Omalizumab Through 48 Weeks in Participants With Chronic Idiopathic Urticaria
XTEND-CIU (Xolair Treatment Efficacy of Longer Duration in Chronic Idiopathic Urticaria): A Phase IV, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Omalizumab Through 48 Weeks in Patients With Chronic Idiopathic Urticaria
Status: Enrolling
Updated:  3/26/2018
O&O Alpan
mi
from
Fairfax, VA
A Study of the Efficacy and Safety of Omalizumab Through 48 Weeks in Participants With Chronic Idiopathic Urticaria
XTEND-CIU (Xolair Treatment Efficacy of Longer Duration in Chronic Idiopathic Urticaria): A Phase IV, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Omalizumab Through 48 Weeks in Patients With Chronic Idiopathic Urticaria
Status: Enrolling
Updated: 3/26/2018
O&O Alpan
mi
from
Fairfax, VA
Click here to add this to my saved trials
A Study of the Efficacy and Safety of Omalizumab Through 48 Weeks in Participants With Chronic Idiopathic Urticaria
XTEND-CIU (Xolair Treatment Efficacy of Longer Duration in Chronic Idiopathic Urticaria): A Phase IV, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Omalizumab Through 48 Weeks in Patients With Chronic Idiopathic Urticaria
Status: Enrolling
Updated:  3/26/2018
Premier Clinical Research
mi
from
Spokane, WA
A Study of the Efficacy and Safety of Omalizumab Through 48 Weeks in Participants With Chronic Idiopathic Urticaria
XTEND-CIU (Xolair Treatment Efficacy of Longer Duration in Chronic Idiopathic Urticaria): A Phase IV, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Omalizumab Through 48 Weeks in Patients With Chronic Idiopathic Urticaria
Status: Enrolling
Updated: 3/26/2018
Premier Clinical Research
mi
from
Spokane, WA
Click here to add this to my saved trials
A Study of the Efficacy and Safety of Omalizumab Through 48 Weeks in Participants With Chronic Idiopathic Urticaria
XTEND-CIU (Xolair Treatment Efficacy of Longer Duration in Chronic Idiopathic Urticaria): A Phase IV, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Omalizumab Through 48 Weeks in Patients With Chronic Idiopathic Urticaria
Status: Enrolling
Updated:  3/26/2018
IMMUNOe Research Centers
mi
from
Centennial, CO
A Study of the Efficacy and Safety of Omalizumab Through 48 Weeks in Participants With Chronic Idiopathic Urticaria
XTEND-CIU (Xolair Treatment Efficacy of Longer Duration in Chronic Idiopathic Urticaria): A Phase IV, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Omalizumab Through 48 Weeks in Patients With Chronic Idiopathic Urticaria
Status: Enrolling
Updated: 3/26/2018
IMMUNOe Research Centers
mi
from
Centennial, CO
Click here to add this to my saved trials
A Study of the Efficacy and Safety of Omalizumab Through 48 Weeks in Participants With Chronic Idiopathic Urticaria
XTEND-CIU (Xolair Treatment Efficacy of Longer Duration in Chronic Idiopathic Urticaria): A Phase IV, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Omalizumab Through 48 Weeks in Patients With Chronic Idiopathic Urticaria
Status: Enrolling
Updated:  3/26/2018
Ocean Allergy & Resp Res Ctr
mi
from
Brick, NJ
A Study of the Efficacy and Safety of Omalizumab Through 48 Weeks in Participants With Chronic Idiopathic Urticaria
XTEND-CIU (Xolair Treatment Efficacy of Longer Duration in Chronic Idiopathic Urticaria): A Phase IV, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Omalizumab Through 48 Weeks in Patients With Chronic Idiopathic Urticaria
Status: Enrolling
Updated: 3/26/2018
Ocean Allergy & Resp Res Ctr
mi
from
Brick, NJ
Click here to add this to my saved trials
A Study of the Efficacy and Safety of Omalizumab Through 48 Weeks in Participants With Chronic Idiopathic Urticaria
XTEND-CIU (Xolair Treatment Efficacy of Longer Duration in Chronic Idiopathic Urticaria): A Phase IV, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Omalizumab Through 48 Weeks in Patients With Chronic Idiopathic Urticaria
Status: Enrolling
Updated:  3/26/2018
Montefiore Medical Group;Department of Medicine
mi
from
Bronx, NY
A Study of the Efficacy and Safety of Omalizumab Through 48 Weeks in Participants With Chronic Idiopathic Urticaria
XTEND-CIU (Xolair Treatment Efficacy of Longer Duration in Chronic Idiopathic Urticaria): A Phase IV, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Omalizumab Through 48 Weeks in Patients With Chronic Idiopathic Urticaria
Status: Enrolling
Updated: 3/26/2018
Montefiore Medical Group;Department of Medicine
mi
from
Bronx, NY
Click here to add this to my saved trials
IL1-TRAP, Rilonacept, in Systemic Sclerosis
Randomized, Double-Blind, Placebo-Controlled Trial if IL1-TRAP, Rilonacept, in Systemic Sclerosis -A Phase I/II Biomarker Trial
Status: Enrolling
Updated:  4/2/2018
Boston University Medical Center
mi
from
Boston, MA
IL1-TRAP, Rilonacept, in Systemic Sclerosis
Randomized, Double-Blind, Placebo-Controlled Trial if IL1-TRAP, Rilonacept, in Systemic Sclerosis -A Phase I/II Biomarker Trial
Status: Enrolling
Updated: 4/2/2018
Boston University Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
Green Tea Extract in Treating Patients With Actinic Keratosis
A Randomized, Double-Blind, Placebo-Controlled Phase II Clinical Trial of Polyphenon E Against Various Endpoints of Actinic Keratosis Pathobiology
Status: Enrolling
Updated:  4/3/2018
Chao Family Comprehensive Cancer Center
mi
from
Orange, CA
Green Tea Extract in Treating Patients With Actinic Keratosis
A Randomized, Double-Blind, Placebo-Controlled Phase II Clinical Trial of Polyphenon E Against Various Endpoints of Actinic Keratosis Pathobiology
Status: Enrolling
Updated: 4/3/2018
Chao Family Comprehensive Cancer Center
mi
from
Orange, CA
Click here to add this to my saved trials
Observational Study of Keratoconus and Post-keratoplasty Eyes
Observational Study of Keratoconus and Post-keratoplasty Eyes
Status: Enrolling
Updated:  4/4/2018
Casey Eye Institute, Oregon Health & Science University
mi
from
Portland, OR
Observational Study of Keratoconus and Post-keratoplasty Eyes
Observational Study of Keratoconus and Post-keratoplasty Eyes
Status: Enrolling
Updated: 4/4/2018
Casey Eye Institute, Oregon Health & Science University
mi
from
Portland, OR
Click here to add this to my saved trials
Effects of IV-Administered Ca-DTPA and Zn-DTPA To Treat Patients With Gadolinium Deposition Disease
Investigator Initiated Investigational New Drug Application to Study the Effects of IV-Administered Ca-DTPA and Zn-DTPA To Treat Patients With Gadolinium Deposition Disease
Status: Enrolling
Updated:  4/5/2018
UNC Hospitals
mi
from
Chapel Hill, NC
Effects of IV-Administered Ca-DTPA and Zn-DTPA To Treat Patients With Gadolinium Deposition Disease
Investigator Initiated Investigational New Drug Application to Study the Effects of IV-Administered Ca-DTPA and Zn-DTPA To Treat Patients With Gadolinium Deposition Disease
Status: Enrolling
Updated: 4/5/2018
UNC Hospitals
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Clinical Evaluation of T.R.U.E. TEST® Fragrance Mix and Thimerosal Allergens:Bioequivalence of PVP Formulations
Clinical Evaluation of T.R.U.E. TEST® Fragrance Mix and Thimerosal Allergens: Bioequivalence of Polyvinylpyrrolidone (PVP) Formulations
Status: Enrolling
Updated:  4/6/2018
River City Dermatology
mi
from
Little Rock, AR
Clinical Evaluation of T.R.U.E. TEST® Fragrance Mix and Thimerosal Allergens:Bioequivalence of PVP Formulations
Clinical Evaluation of T.R.U.E. TEST® Fragrance Mix and Thimerosal Allergens: Bioequivalence of Polyvinylpyrrolidone (PVP) Formulations
Status: Enrolling
Updated: 4/6/2018
River City Dermatology
mi
from
Little Rock, AR
Click here to add this to my saved trials
Clinical Evaluation of T.R.U.E. TEST® Fragrance Mix and Thimerosal Allergens:Bioequivalence of PVP Formulations
Clinical Evaluation of T.R.U.E. TEST® Fragrance Mix and Thimerosal Allergens: Bioequivalence of Polyvinylpyrrolidone (PVP) Formulations
Status: Enrolling
Updated:  4/6/2018
Dermatology Specialists PSC
mi
from
Louisville, KY
Clinical Evaluation of T.R.U.E. TEST® Fragrance Mix and Thimerosal Allergens:Bioequivalence of PVP Formulations
Clinical Evaluation of T.R.U.E. TEST® Fragrance Mix and Thimerosal Allergens: Bioequivalence of Polyvinylpyrrolidone (PVP) Formulations
Status: Enrolling
Updated: 4/6/2018
Dermatology Specialists PSC
mi
from
Louisville, KY
Click here to add this to my saved trials
Clinical Evaluation of T.R.U.E. TEST® Fragrance Mix and Thimerosal Allergens:Bioequivalence of PVP Formulations
Clinical Evaluation of T.R.U.E. TEST® Fragrance Mix and Thimerosal Allergens: Bioequivalence of Polyvinylpyrrolidone (PVP) Formulations
Status: Enrolling
Updated:  4/6/2018
Winthrop University Hospital
mi
from
Mineola, NY
Clinical Evaluation of T.R.U.E. TEST® Fragrance Mix and Thimerosal Allergens:Bioequivalence of PVP Formulations
Clinical Evaluation of T.R.U.E. TEST® Fragrance Mix and Thimerosal Allergens: Bioequivalence of Polyvinylpyrrolidone (PVP) Formulations
Status: Enrolling
Updated: 4/6/2018
Winthrop University Hospital
mi
from
Mineola, NY
Click here to add this to my saved trials
Clinical Evaluation of T.R.U.E. TEST® Fragrance Mix and Thimerosal Allergens:Bioequivalence of PVP Formulations
Clinical Evaluation of T.R.U.E. TEST® Fragrance Mix and Thimerosal Allergens: Bioequivalence of Polyvinylpyrrolidone (PVP) Formulations
Status: Enrolling
Updated:  4/6/2018
American Dermatology Associates
mi
from
Shawnee Mission, KA
Clinical Evaluation of T.R.U.E. TEST® Fragrance Mix and Thimerosal Allergens:Bioequivalence of PVP Formulations
Clinical Evaluation of T.R.U.E. TEST® Fragrance Mix and Thimerosal Allergens: Bioequivalence of Polyvinylpyrrolidone (PVP) Formulations
Status: Enrolling
Updated: 4/6/2018
American Dermatology Associates
mi
from
Shawnee Mission, KA
Click here to add this to my saved trials
Clinical Evaluation of T.R.U.E. TEST® Panel 3.2 Allergens: Dose Response
Clinical Evaluation of T.R.U.E. TEST® Panel 3.2 Allergens: Bronopol and Disperse Blue 106 Dose Response Study
Status: Enrolling
Updated:  4/6/2018
Dermatology Specialists PSC
mi
from
Louisville, KY
Clinical Evaluation of T.R.U.E. TEST® Panel 3.2 Allergens: Dose Response
Clinical Evaluation of T.R.U.E. TEST® Panel 3.2 Allergens: Bronopol and Disperse Blue 106 Dose Response Study
Status: Enrolling
Updated: 4/6/2018
Dermatology Specialists PSC
mi
from
Louisville, KY
Click here to add this to my saved trials
Clinical Evaluation of T.R.U.E. TEST® Panel 3.2 Allergens: Dose Response
Clinical Evaluation of T.R.U.E. TEST® Panel 3.2 Allergens: Bronopol and Disperse Blue 106 Dose Response Study
Status: Enrolling
Updated:  4/6/2018
Odense University Hospital
mi
from
Odense C,
Clinical Evaluation of T.R.U.E. TEST® Panel 3.2 Allergens: Dose Response
Clinical Evaluation of T.R.U.E. TEST® Panel 3.2 Allergens: Bronopol and Disperse Blue 106 Dose Response Study
Status: Enrolling
Updated: 4/6/2018
Odense University Hospital
mi
from
Odense C,
Click here to add this to my saved trials
CEI Van Outreach Screening Study
Prospective Evaluation of Optical Coherence Tomography Usage in the Screening of Eye Diseases
Status: Enrolling
Updated:  4/10/2018
Casey Eye Institute Outreach Screening Van
mi
from
Portland, OR
CEI Van Outreach Screening Study
Prospective Evaluation of Optical Coherence Tomography Usage in the Screening of Eye Diseases
Status: Enrolling
Updated: 4/10/2018
Casey Eye Institute Outreach Screening Van
mi
from
Portland, OR
Click here to add this to my saved trials
Brief Behavioral Activation Intervention for Depressed Asthma and Urticaria Patients
Brief Behavioral Activation Intervention for Depressed Asthma and Urticaria Patients
Status: Enrolling
Updated:  4/17/2018
University of Mississippi Medical Center - Allergy, Immunology and Asthma Care Clinic
mi
from
Jackson, MS
Brief Behavioral Activation Intervention for Depressed Asthma and Urticaria Patients
Brief Behavioral Activation Intervention for Depressed Asthma and Urticaria Patients
Status: Enrolling
Updated: 4/17/2018
University of Mississippi Medical Center - Allergy, Immunology and Asthma Care Clinic
mi
from
Jackson, MS
Click here to add this to my saved trials
A Pilot Study Testing Salicylic Acid Peels Versus Glycolic Acid Peels for the Treatment of Melasma
A Pilot Study Comparing the Efficacy of Glycolic Acid Peels vs. Salicylic Acid Peels for the Treatment of Melasma: A Randomized Control Trial
Status: Enrolling
Updated:  4/25/2018
Northwestern University Department of Dermatology
mi
from
Chicago, IL
A Pilot Study Testing Salicylic Acid Peels Versus Glycolic Acid Peels for the Treatment of Melasma
A Pilot Study Comparing the Efficacy of Glycolic Acid Peels vs. Salicylic Acid Peels for the Treatment of Melasma: A Randomized Control Trial
Status: Enrolling
Updated: 4/25/2018
Northwestern University Department of Dermatology
mi
from
Chicago, IL
Click here to add this to my saved trials
The Effect of Topical Anesthetics on Patients' Pain and Operative Experience During Treatment With QSwitched Laser
The Effect of Topical Anesthetic Using Lidocaine 2.5%/Prilocaine 2.5% Versus Lidocaine 7%/Tetracaine 7% Cream on Patients' Pain and Operative Experience During Treatment With QSwitched 532nm Laser
Status: Enrolling
Updated:  4/25/2018
Northwestern University, Feinberg School of Medicine, Department of Dermatology
mi
from
Chicago, IL
The Effect of Topical Anesthetics on Patients' Pain and Operative Experience During Treatment With QSwitched Laser
The Effect of Topical Anesthetic Using Lidocaine 2.5%/Prilocaine 2.5% Versus Lidocaine 7%/Tetracaine 7% Cream on Patients' Pain and Operative Experience During Treatment With QSwitched 532nm Laser
Status: Enrolling
Updated: 4/25/2018
Northwestern University, Feinberg School of Medicine, Department of Dermatology
mi
from
Chicago, IL
Click here to add this to my saved trials
Study Performance of The Plexur P™ Bone Void Filler Device in Patients Undergoing Iliac Crest Harvesting Procedures
A Prospective Pilot Study on the Performance of The Plexur P™ Bone Void Filler
Status: Enrolling
Updated:  4/26/2018
Hospital for Special Surgery
mi
from
New York, NY
Study Performance of The Plexur P™ Bone Void Filler Device in Patients Undergoing Iliac Crest Harvesting Procedures
A Prospective Pilot Study on the Performance of The Plexur P™ Bone Void Filler
Status: Enrolling
Updated: 4/26/2018
Hospital for Special Surgery
mi
from
New York, NY
Click here to add this to my saved trials
A Phase Ib/IIa, Double-Blind, Randomized Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of S-777469 in Subjects With Atopic Dermatitis
A Phase Ib/IIa, Multiple-Dose, Double-Blind, Randomized, Placebo-Controlled Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of S-777469 in Subjects With Mild to Moderate Atopic Dermatitis
Status: Enrolling
Updated:  4/26/2018
Comprehensive Phase One
mi
from
Miramar, FL
A Phase Ib/IIa, Double-Blind, Randomized Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of S-777469 in Subjects With Atopic Dermatitis
A Phase Ib/IIa, Multiple-Dose, Double-Blind, Randomized, Placebo-Controlled Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of S-777469 in Subjects With Mild to Moderate Atopic Dermatitis
Status: Enrolling
Updated: 4/26/2018
Comprehensive Phase One
mi
from
Miramar, FL
Click here to add this to my saved trials
Safety and Effectiveness Evaluation of the Device in Achieving Submental Lift
An Open-Label, Single-Center, Single-Treatment, Safety and Effectiveness Evaluation of Percutaneous Radiofrequency in Achieving Submental Lift
Status: Enrolling
Updated:  4/27/2018
New Jersey Plastic Surgery
mi
from
Montclair, NJ
Safety and Effectiveness Evaluation of the Device in Achieving Submental Lift
An Open-Label, Single-Center, Single-Treatment, Safety and Effectiveness Evaluation of Percutaneous Radiofrequency in Achieving Submental Lift
Status: Enrolling
Updated: 4/27/2018
New Jersey Plastic Surgery
mi
from
Montclair, NJ
Click here to add this to my saved trials
Sustained Effect of Urticaria Remission With Relatively High Dose Vitamin D Supplementation After Omalizumab Discontinuation
Sustained Effect of Urticaria Remission With Relatively High Dose Vitamin D Supplementation After Omalizumab Discontinuation
Status: Enrolling
Updated:  4/30/2018
University of Kansas Medical Center
mi
from
Kansas City, KA
Sustained Effect of Urticaria Remission With Relatively High Dose Vitamin D Supplementation After Omalizumab Discontinuation
Sustained Effect of Urticaria Remission With Relatively High Dose Vitamin D Supplementation After Omalizumab Discontinuation
Status: Enrolling
Updated: 4/30/2018
University of Kansas Medical Center
mi
from
Kansas City, KA
Click here to add this to my saved trials